EPHA2 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is an oral dual Bcr/Abl and Src family kinases inhibitor approved for treating patients with chronic myelogenous leukaemia and has been shown to have significant activity against EphA2 [40, 41].